BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Credit Suisse maintains outperform on Aurobindo Pharma
Company will be a beneficiary of faster approvals in US. Margin expansion will be driven by improving product mix. Expect 38 per cent profit growth over next 2 quarters. Expect operating profit CAGR of 22 per cent over FY2016-18. Auro Pharma is favourably placed on growth and return against its peers.